CRISPR/Cas9 in drug discovery: Applications in target discovery, validation, and hit screening
You are invited to hear our panel of experts on May 11, 2016, in this live, online educational seminar. For more information and complimentary registration visit:
webinar.sciencemag.org
Date: Wednesday, May 11, 2016
Time: 12 noon Eastern, 9 a.m. Pacific, 5 p.m. UK, 6 p.m. Central Europe
Duration: 1 hour
Register Now
About This Webinar
The CRISPR/Cas9 system allows for unprecedented ease and control when editing the genome. Its potential impact on drug discovery is vast, including enabling gene and cell replacement therapies, identifying novel drug targets through functional genomic screens, and simplifying the production of disease models using permanent knockouts for validating therapy targets and testing drug efficacy. But in practical terms, how is CRISPR/Cas9 currently being applied, and where might the future challenges and pitfalls be? Furthermore, how do assays based on the new CRISPR/Cas9 technology compare with current screening methodologies, particularly those using small interfering RNA (siRNA)?
During the webinar, our expert panel will address:
• Areas of the drug discovery process where gene editing will have the most immediate and long term impact
• The current and future role of CRISPR/Cas9 in target discovery, hit identification, and lead optimization (compared with siRNA screening)
• The challenges that CRISPR/Cas9 brings to screening and assay development, particularly with respect to cell analysis
• The importance of carrying out binding studies following gene editing.
The presentations will be followed by a live Q&A session with the online audience.
Participants:
Lorenz Mayr, Ph.D.
AstraZeneca
Cambridge, U.K.
Ralph Garippa, Ph.D.
Memorial Sloan Kettering Cancer Center
New York, NY
Register at:
webinar.sciencemag.org
Questions? E-mail:
webinar@aaas.org.
Produced by the Science/AAAS Custom Publishing Office and sponsored by: General Electric
